United States, ex rel v. Actavis Mid-Atlantic, et al
Case Number:
1:02-cv-11738
Court:
Nature of Suit:
Judge:
Firms
- Akin Gump
- ArentFox Schiff
- Bailey & Glasser
- Brooks & DeRensis
- Butzel Long
- Choate Hall
- Cooley LLP
- Covington & Burling
- Fitch Law Partners
- Foley & Lardner
- Freeman Mathis
- Hyman Phelps
- Kirkland & Ellis
- K&L Gates
- Manatt Phelps
- Meehan Boyle
- Morrison Foerster
- Morrison Mahoney
- Nixon Peabody
- Reed Smith
- Saul Ewing
- Seyfarth Shaw
- Sherin & Lodgen
- Skadden Arps
- Troutman Pepper
- Verrill Dana
- White & Case
- WilmerHale
Companies
- Abbott Laboratories
- Allergan PLC
- Alpharma Inc.
- Bausch Health Cos. Inc.
- Breckenridge Pharmaceutical Inc.
- Eli Lilly & Co.
- Endo International PLC
- Ferndale Pharma Group Inc.
- Forest Laboratories Inc.
- Hi-Tech Pharmacal Co., Inc.
- McKesson Corp.
- Mission Pharmacal Co.
- Par Pharmaceutical Cos. Inc.
- Pfizer Inc.
- Shionogi & Co. Ltd.
- Teva Pharmaceutical Industries Ltd.
- The Harvard Drug Group LLC
- The Procter & Gamble Co.
- UCB SA
- Warner Chilcott Limited
Government Agencies
Sectors & Industries:
-
August 24, 2011
Mass. Asks To Join Healthpoint Fraud Suit Over Xenaderm
Massachusetts sought Wednesday to intervene in a U.S. Department of Justice suit claiming Healthpoint Ltd. caused Medicaid to pay $90 million in claims for bedsore ointment Xenaderm despite its ineligibility for coverage.
-
April 01, 2011
DOJ Sues Healthpoint Over Zenaderm Marketing
The U.S. Department of Justice on Thursday accused Healthpoint Ltd. of falsely marketing the bedsore ointment Xenaderm as a prescription drug qualifying for Medicare and Medicaid reimbursement, causing the agencies to pay $90 million for an ineligible drug.
- ← Previous
- 1
- 2
- Next →